Continuous Versus Intermittent cARdiac Electrical moNitorinG
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).
Eligibility criteria
Qualifiers
Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)
At least 18 years of age.
No allergy to adhesive patches.
Able to understand and willing to sign an IRB-approved written informed consent document.
Disqualifiers
Younger than 18 years of age
Allergy to adhesive patches
Trial design
Treatments tested in this trial
- BodyGuardian Mini Plus
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov